Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22546296 | 0.81 | MAPT (0.32) | AGBL2 | |
| SCHEMBL1748589 | 0.79 | NOS3 (0.34) | — | |
| SCHEMBL30875153 | 0.79 | — | — | |
| SCHEMBL24869418 | 0.79 | — | — | |
| SCHEMBL2686647 | 0.79 | PLAU (0.31) | — | |
| SCHEMBL24343914 | 0.76 | PIK3CA (0.33) | — | |
| SCHEMBL15055583 | 0.71 | — | — | |
| SCHEMBL14851276 | 0.71 | ATM (0.44) | — | |
| SCHEMBL17927668 | 0.69 | — | — | |
| SCHEMBL3658791 | 0.68 | GRM5 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491935-B | Novel analogs as modulators of androgen and glucocorticoid receptors | 昂科斯特拉公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-3707143-B9 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2023-04-12 | — | — | EP | disclosed |
| EP-3707143-B1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE S L (ES) | 2022-12-28 | — | — | EP | disclosed |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | ONCOSTELLAE, S.L. | 2022-09-27 | — | — | US | disclosed |
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | ONCOSTELLAE, S.L. (ES) | 2020-10-15 | — | — | US | disclosed |
| EP-3707143-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | Oncostellae, S.L. (ES) | 2020-09-16 | — | — | EP | disclosed |
| CN-111491935-A | Novel analogs as androgen receptor and glucocorticoid receptor modulators | 昂科斯特拉公司 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325123-A1 | NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS | NR5A1, AR, NR3C1 | AGBL2 3570/4885 |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | AR, NR5A1, NR3C1 | AGBL2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.